ABBISKO CAYMAN DL-00001
Research ABBISKO CAYMAN DL-00001 (8ZD) on Bullrun: market cap EUR 705.45M, P/E 98.5. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker8ZD
- ExchangeF
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 705.45M
- P/E98.5
- Financial periodFY2025
- RevenueEUR 612.12M
- Revenue growth21.5%
- Net incomeEUR 55.25M
- Free cash flowEUR 73.75M
- Gross margin100.0%
Valuation Snapshot
latest market cap is EUR 705.45M; P/E is 98.5.
About ABBISKO CAYMAN DL-00001
Abbisko Cayman Limited, together with its subsidiaries, engages in the research, discovery, and development of pharmaceutical products in Mainland China and the European Union. The company develops Pimicotinib (ABSK021), a small molecule CSF-1R inhibitor, which is in NDA/commercial stage for the treatment of tenosynovial giant cell tumors and Phase Ib/II for the treatment of chronic graft versus host disease;
Frequently asked questions
What is ABBISKO CAYMAN DL-00001's market cap?
ABBISKO CAYMAN DL-00001's market capitalization is EUR 705.45M.
What is ABBISKO CAYMAN DL-00001's P/E ratio?
ABBISKO CAYMAN DL-00001's price-to-earnings (P/E) ratio is 98.5.
What does ABBISKO CAYMAN DL-00001 do?
Abbisko Cayman Limited, together with its subsidiaries, engages in the research, discovery, and development of pharmaceutical products in Mainland China and the European Union.